STYRENIX vs TATVA: Stock Comparison
TATVA CHIN PHARM CHEM is the larger company by market capitalisation. STYRENIX PERFORMANCE shows a lower P/E, a higher ROE and a higher dividend yield, while TATVA CHIN PHARM CHEM shows faster revenue growth, lower leverage and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
STYRENIX leads 6; TATVA leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | STYRENIX | TATVA |
|---|---|---|
| Sector | Chemicals | Chemicals |
| Industry | Specialty Chemicals | Specialty Chemicals |
Price
| Metric | STYRENIX | TATVA |
|---|---|---|
| Live Price | ₹1,811.8 | ₹1,614.8 |
| Day Change | 0.54% | -0.8% |
| Volume | 71,489 | 46,779 |
| 52-Week High | ₹2,653 | ₹2,113.6 |
| 52-Week Low | ₹1,720 | ₹1,044.1 |
| Distance from 52W High | -31.71% | -23.6% |
Valuation
| Metric | STYRENIX | TATVA |
|---|---|---|
| Market Cap | ₹3,151 Cr | ₹3,787 Cr |
| P/E Ratio | 12.54x | 60.19x |
| P/B Ratio | 2.12x | 4.65x |
| EPS | ₹78.64 | ₹9.17 |
| Book Value | ₹776.95 | ₹334.2 |
| Dividend Yield | 2.58% | 0.12% |
Growth
| Metric | STYRENIX | TATVA |
|---|---|---|
| Revenue Growth (TTM YoY) | -12.1% | 24.4% |
| EPS Growth (TTM YoY) | 30.9% | 907.5% |
| Qtr Sales Growth | 0% | 30.09% |
| Qtr Profit Growth | 0% | 34.23% |
Profitability & Leverage
| Metric | STYRENIX | TATVA |
|---|---|---|
| ROE | 13.38% | 5.38% |
| ROCE | 12.38% | 4.16% |
| Net Margin | 5.42% | 8.31% |
| Operating Margin | 7.06% | 11.83% |
| Debt to Equity | 0.23x | 0.15x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | STYRENIX | TATVA |
|---|---|---|
| Promoter Holding | 46.24% | 72.02% |
| FII Holding | 1.31%▲ 0.45 pp | 4.38%▲ 0.45 pp |
| DII Holding | 14.44%▼ 3 pp | 3.21%▲ 0.1 pp |
| Public Holding | 38.01%▲ 2.55 pp | 20.39%▼ 0.55 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: STYRENIX PERFORMANCE and TATVA CHIN PHARM CHEM.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.